DK1420769T3 - Lipid profil modulation med steroider og PPAR alpha agonister - Google Patents
Lipid profil modulation med steroider og PPAR alpha agonisterInfo
- Publication number
- DK1420769T3 DK1420769T3 DK02707001T DK02707001T DK1420769T3 DK 1420769 T3 DK1420769 T3 DK 1420769T3 DK 02707001 T DK02707001 T DK 02707001T DK 02707001 T DK02707001 T DK 02707001T DK 1420769 T3 DK1420769 T3 DK 1420769T3
- Authority
- DK
- Denmark
- Prior art keywords
- steroids
- lipid profile
- ppar alpha
- alpha agonists
- profile modulation
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 102000023984 PPAR alpha Human genes 0.000 title 1
- 108010028924 PPAR alpha Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 abstract 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 abstract 1
- 230000000778 atheroprotective effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0107383.2A GB0107383D0 (en) | 2001-03-23 | 2001-03-23 | Lipid profile modulation |
| PCT/GB2002/001457 WO2002076435A2 (fr) | 2001-03-23 | 2002-03-25 | Modulation d'un profile lipidique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1420769T3 true DK1420769T3 (da) | 2008-09-29 |
Family
ID=9911465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02707001T DK1420769T3 (da) | 2001-03-23 | 2002-03-25 | Lipid profil modulation med steroider og PPAR alpha agonister |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050032761A1 (fr) |
| EP (1) | EP1420769B1 (fr) |
| JP (1) | JP2004528308A (fr) |
| AT (1) | ATE397922T1 (fr) |
| AU (1) | AU2002241160A1 (fr) |
| CA (1) | CA2441834C (fr) |
| DE (1) | DE60227080D1 (fr) |
| DK (1) | DK1420769T3 (fr) |
| ES (1) | ES2307729T3 (fr) |
| GB (2) | GB0107383D0 (fr) |
| PT (1) | PT1420769E (fr) |
| WO (1) | WO2002076435A2 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258168B2 (en) | 2001-07-27 | 2007-08-21 | Enventure Global Technology L.L.C. | Liner hanger with slip joint sealing members and method of use |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| JP2006522744A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| EP1854487A3 (fr) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Combinaisons d'un inhibiteur de 11-beta-hydroxystéroïde déhydrogénase, type 1, et d'un agoniste d'un récepteur glucocorticoïde |
| WO2005027882A1 (fr) * | 2003-09-22 | 2005-03-31 | Bionetworks Gmbh | Prevention et traitement de la perte osseuse induite par inflammation et/ou immuno-mediee |
| EP1928840B1 (fr) | 2005-04-05 | 2011-08-10 | F. Hoffmann-La Roche AG | 1H-Pyrazole-4-carboxamides, préparation et utilisation de ceux-ci en tant qu'inhibiteurs de 11-beta-hydroxystéroïde déshydrogénase |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| US8324265B2 (en) | 2005-11-21 | 2012-12-04 | Shionogi & Co., Ltd. | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity |
| BRPI0710479A2 (pt) | 2006-01-18 | 2012-08-14 | Hoffmann La Roche | composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica. |
| CN101646942A (zh) * | 2006-03-23 | 2010-02-10 | 埃梅利塔·德古兹曼·布雷耶 | 载脂蛋白指纹图谱技术 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| ES2535317T3 (es) | 2007-05-18 | 2015-05-08 | Shionogi & Co., Ltd. | Derivado heterocíclico que contiene nitrógeno que tiene actividad inhibidora de la 11 beta-hidroxiesteroide deshidrogenasa de tipo 1 |
| US8927549B2 (en) | 2008-11-21 | 2015-01-06 | High Point Pharmaceuticals, Llc | Adamantyl benzamide derivatives |
| WO2011061749A2 (fr) * | 2009-11-19 | 2011-05-26 | Ganga Raju Gokaraju | Agents dérivés d'holoptelea integrifolia et leurs compositions destinées à lutter contre le syndrome métabolique et les maladies associées |
| WO2012015715A1 (fr) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Dérivés de thiazol-2-ylamine substitués, compositions pharmaceutiques et procédés d'utilisation en tant que modulateurs de 11-bêta-hsd1 |
| US9781909B2 (en) * | 2013-07-17 | 2017-10-10 | University Of Manitoba | Mito-Ob: a transgenic mouse model for obesity |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| EP3565559A4 (fr) * | 2017-01-09 | 2020-07-08 | Temple University - Of The Commonwealth System of Higher Education | Méthodes et compositions pharmaceutiques destinées à traiter la stéatohépatite non alcoolique |
| KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| AU2019384074B2 (en) * | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| EP4525983A4 (fr) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | Procédés et compositions pour traiter un excès de glucocorticoïdes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| GB9517622D0 (en) * | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| EP1309697A2 (fr) * | 2000-07-05 | 2003-05-14 | Bayer Aktiengesellschaft | Regulation d'enzyme du type 11 beta-hydroxysteroide deshydrogenase 1 humaine |
| GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
-
2001
- 2001-03-23 GB GBGB0107383.2A patent/GB0107383D0/en not_active Ceased
-
2002
- 2002-03-25 JP JP2002574951A patent/JP2004528308A/ja active Pending
- 2002-03-25 AU AU2002241160A patent/AU2002241160A1/en not_active Abandoned
- 2002-03-25 EP EP02707001A patent/EP1420769B1/fr not_active Expired - Lifetime
- 2002-03-25 AT AT02707001T patent/ATE397922T1/de active
- 2002-03-25 DE DE60227080T patent/DE60227080D1/de not_active Expired - Lifetime
- 2002-03-25 ES ES02707001T patent/ES2307729T3/es not_active Expired - Lifetime
- 2002-03-25 PT PT02707001T patent/PT1420769E/pt unknown
- 2002-03-25 CA CA2441834A patent/CA2441834C/fr not_active Expired - Fee Related
- 2002-03-25 DK DK02707001T patent/DK1420769T3/da active
- 2002-03-25 GB GB0323962A patent/GB2390367B/en not_active Expired - Fee Related
- 2002-03-25 WO PCT/GB2002/001457 patent/WO2002076435A2/fr not_active Ceased
-
2003
- 2003-09-23 US US10/668,564 patent/US20050032761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002241160A1 (en) | 2002-10-08 |
| EP1420769B1 (fr) | 2008-06-11 |
| EP1420769A2 (fr) | 2004-05-26 |
| WO2002076435A3 (fr) | 2004-03-18 |
| CA2441834C (fr) | 2011-01-25 |
| GB0107383D0 (en) | 2001-05-16 |
| GB2390367A (en) | 2004-01-07 |
| CA2441834A1 (fr) | 2002-10-03 |
| PT1420769E (pt) | 2008-08-05 |
| JP2004528308A (ja) | 2004-09-16 |
| US20050032761A1 (en) | 2005-02-10 |
| ATE397922T1 (de) | 2008-07-15 |
| DE60227080D1 (de) | 2008-07-24 |
| WO2002076435A2 (fr) | 2002-10-03 |
| GB2390367B (en) | 2005-04-13 |
| GB0323962D0 (en) | 2003-11-19 |
| ES2307729T3 (es) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1420769T3 (da) | Lipid profil modulation med steroider og PPAR alpha agonister | |
| DK1098649T3 (da) | Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant | |
| DE60217233D1 (de) | Abdichtung für Verdichter und Kreiselverdichter mit dieser Abdichtung | |
| NO20040865L (no) | Friksjon reduserende sammensetning og metode | |
| ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
| CY1112487T1 (el) | Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη | |
| DK1501815T3 (da) | Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer | |
| DE602004019812D1 (de) | Marker für neuromyelitis optica | |
| BR0215405A (pt) | Composições e processos de uso de collajolie | |
| CY1113651T1 (el) | Αντιφλεγμονωδη σκευασματα | |
| PH12022552267A1 (en) | Tie2-binding agents and methods of use | |
| NO20062649L (no) | Biarylsulfonamider og metoder for anvendelse av disse | |
| DK1265911T3 (da) | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler | |
| NO20044898L (no) | Nye etonogestrel estere | |
| ITRM20020105A0 (it) | Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego. | |
| NO20040542L (no) | Fremgangsmate for installasjon av en ankerline og kobling for bruk i fremgangsmaten | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| PT1553942E (pt) | Composicao farmaceutica associando tenatoprazol e um anti-inflamatorio | |
| NO20040055L (no) | Sarbandasje | |
| ITMI20021822A1 (it) | Manicotto elastico e procedimento per la fabbricazione di un manicotto elastico | |
| UY28531A1 (es) | Composición líquida biologicamente estable de fviii, de fww o del complejo fviii/fww humanos | |
| SE0301650D0 (sv) | Novel compounds | |
| FI20031191A7 (fi) | Monoamiinin takaisinoton estäjä | |
| MXPA04007387A (es) | El empleo de inhibidores del intercambiador de sodio/hidrogeno para el tratamiento de desordenes tromboticos e inflamatorios. | |
| ITRM20050478A1 (it) | Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia. |